Practical approach to the diagnosis, management, and treatment of pediatric patients with bone fragility: an expert opinion Authors: Giampiero I Baroncelli, Daniele Tessaris, Tommaso Aversa, Enrica Bertelli, Pasquale Comberiati, Domenico Corica, Natascia Di Iorgi, Maria Felicia Faienza, Danilo Fintini, Roberto Franceschi, Anna Grandone, Mila Ann Karapurackal, Silvia Longhi, Marco Pitea, Andrea Secco, Giuliana Trifirò, Graziamaria Ubertini, Flavia Urbano, Francesco Vierucci, Malgorzata Wasniewska, Stefano Mora, Luisa de Sanctis Published: 2026 ABSTRACT AbstractPurposeChildren and adolescents frequently experience fractures related to accidental injuries; however, fractures may also result from non-accidental trauma in abused children or from underlying bone fragility due to primary or secondary osteoporosis. In pediatric patients with fragility fractures diagnosis and treatment may be delayed. This document aims to provide clinicians with a practical approach to the diagnosis and management of fragility fractures in children and adolescents.MethodsBetween November 2024 and June 2025, a group of Italian pediatric endocrinologists with expertise in bone and mineral metabolism held regular online meetings to discuss key issues related to the diagnosis and management of pediatric bone fragility and developed experts opinion statements based on clinical experience and a review of the relevant literature.ResultsThe expert panel formulated consensus statements on the clinical management of children and adolescents with fragility fractures. Seven main areas were addressed: 1) definition of fragility fractures and pediatric osteoporosis; 2) diagnostic approach; 3) main causes of primary and secondary osteoporosis; 4) assessment of the potential for spontaneous recovery from bone fragility; 5) management of bisphosphonate therapy; 6) other therapeutic options; 7) conservative measures.ConclusionThe diagnosis of osteoporosis in pediatric patients should follow a clinically oriented approach. Genetic testing plays a crucial role in identifying primary forms of osteoporosis. Vertebral reshaping may occur in some patients with secondary osteoporosis. Bisphosphonates represent the mainstay of treatment in children and adolescents with bone fragility. Conservative measures aimed at optimizing bone strength may be beneficial in selected cases.Keywords: Adolescents, Bisphosphonates, Children, Fragility fractures, Osteoporosis, Vertebral reshaping Background Fractures are common in the pediatric population, with an incidence of approximately 50% in boys and 40% in girls [1, 2]. The distal radius is the most common site of fracture in children and adolescents [1–4]. Peaks in fracture incidence typically coincide with periods of maximal growth velocity, particularly between 11-15 years of age [5]. A major challenge in infants, children, and adolescents is distinguishing accidental trauma from a non-accidental injury. Fractures related to abuse may remain unrecognized for a prolonged period, resulting in a delayed diagnosis. Bone fragility represents the clinical manifestation of primary or secondary osteoporosis. Pediatric osteoporosis differs from adult osteoporosis in several peculiar aspects: 1. the prevalence of monogenic primary osteoporotic disorders which manifest themselves at birth or in the early stages of life; 2. bone modeling which is closely linked to skeletal growth may promote the potential for spontaneous recovery from bone fragility [6]; 3. changes in bone geometry, structure, and bone mass during growth influence the assessment of bone health; 4. the management and treatment of bone fragility associated with primary or secondary osteoporosis in children and adolescents face greater limitations compared with adult patients. The aim of this document is to provide clinicians with a practical approach to the diagnosis and management of bone fragility in children and adolescents based on current knowledge and expert consensus. The panel also formulated specific recommendations regarding diagnostic work-up, genetic testing, and treatment options for primary osteoporosis. Methods This document is the result of an extensive discussion among members of the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology (SIEDP) aimed at standardizing a practical approach to the diagnosis and management of bone fragility in children and adolescents based on the relevant literature and the clinical expertise of the panel. Between November 2024 and June 2025, a group of Italian pediatric endocrinologists specializing in bone and mineral metabolism held periodic meetings and ten teleconferences to discuss key issues related to the diagnosis, management, and treatment of pediatric bone fragility. Expert opinions were formalized through a structured consensus process and supported by evidence from the literature. Seven main topics were addressed: 1) definition of fragility fracture and pediatric osteoporosis; 2) diagnostic approach to pediatric osteoporosis; 3) main causes of primary or secondary osteoporosis; 4) evaluation of the potential for spontaneous or bisphosphonate-induced recovery from bone fragility; 5) management of bisphosphonates treatment; 6) other therapeutic options for children and adolescents with bone fragility; 7) conservative measures. The most relevant studies were independently identified by all the authors through a search of the PubMed (MEDLINE) database in accordance with PRISMA 2020 guidelines. Randomized controlled trials, international guidelines based on GRADE criteria, consensus statements, systematic reviews, meta-analyses, and clinical trials were considered. The following MeSH terms were used to identify suitable studies: "fragility fractures", "bone/skeletal fragility", "primary osteoporosis", "early-onset osteoporosis", "monogenic disorders and bone fragility", "secondary osteoporosis", "bone densitometry and fractures", "genetic analysis of bone fragility", "high-throughput nucleotide sequencing and fragility fractures", "children with fracture", "fractures and abuse", "bisphosphonate", "bisphosphonate and bone/skeletal fragility", "bisphosphonates and primary/secondary osteoporosis", "calcium/vitamin D and fragility fractures/osteoporosis". Serches were restricted to infants, children, and adolescents, with no limitation on publication date. Consensus for each draft statement was achieved using a Delphi technique. All panel members (n = 22) participated in six rounds of online voting, providing their level of agreements for each draft statement, using a agree/disagree scale, and submitting their comments for writing all the statements. Consensus was defined as ≥80% agreement among panel experts; statements that did not initially reach consensus were revised, rephrased, and resubmitted. Final statements were based on clinical expertise and literature evidence with priority given to studies applying GRADE methodology. As this study did not involve human participants, ethical approval was not required. Definition of fragility fracture and pediatric osteoporosis Fragility fractures are defined as those resulting from low-energy trauma (a mechanical force that would not ordinarily cause a fracture), such as a fall from standing height or less, and occurring at no more than walking speed. This definition has proven valid in pediatric chronic illness as vertebral fractures have been shown to predict incident low-trauma long bone fractures defined according to these criteria [6, 7]. However, it is important to recognize that children who sustained high-energy fractures may also have an underlying condition associated with bone fragility [6]. In both adults and children, low-trauma vertebral compression fractures (crush), in the absence of local disease or high-energy trauma, whether symptomatic or asymptomatic, represent a radiographic hallmark of osteoporosis. The International Society of Clinical Densitometry (ISCD) [8] endorses that ≥ 1 vertebral fracture, defined as a >20% loss of vertebral height ratio according to the Genant semiquantitative method [9], is consistent with a diagnosis of osteoporosis in children. In both primary and secondary osteoporosis, even a single, low-trauma fracture may be sufficient to diagnose the child with osteoporosis, even in the presence of a normal bone mineral density (BMD) Z-score [6, 8]. Nevertheless, in children and adolescents with a vertebral fracture, BMD measurement remains useful for the overall assessment of bone health [8]. In the absence of vertebral compression (crush) fractures, the diagnosis of osteoporosis is indicated by the presence of both a clinically significant fracture history and BMD Z-score ≤ -2.0. A clinically significant fracture history include one or more of the following: 1) two or more long bone low-trauma fractures by age 10 years; 2) three or more long bone low-trauma fractures at any age up to age 19 years. However, it should be considered that a value of BMD Z-score of > -2.0 does not preclude the possibility of bone fragility and increased fracture risk [8]. These limitations are useful to avoid overdiagnosis of osteoporosis in children and adolescents who do not show signs or symptoms related to congenital disorders associated with fragility fractures and in subjects who sustain fractures during sports activities. Therefore, ISCD recommendations should be considered for a correct definition of pediatric osteoporosis and healthcare policy. Statement 1. Fragility fractures are caused by low-energy trauma, defined as a mechanical force that would not ordinarily result in a fracture. Statement 2. A single low-trauma fracture may be sufficient to establish a diagnosis of osteoporosis in children and adolescents, even in the presence of a normal BMD Z-score. Diagnostic approach to pediatric osteoporosis The best approach in evaluating a child with a fracture is to proceed step-by-step from diagnosis to treatment. Family and medical history, clinical examination, laboratory investigations, radiographic and bone densitometry assessment, and genetic testing are key elements to formulate the diagnosis. Bone biopsy may be useful in selected circumstances. Family and medical history and clinical examination The first step in evaluating a child with a fracture is to determine whether the fracture occurred in an otherwise healthy child or in the context of a condition known to be associated with bone fragility (Fig 1). Evidence of a major accidental injury or trauma during sport or play in a healthy child generally argues against a condition of osteoporosis. Conversely, a non-accidental fracture in an otherwise healthy child should raise suspicion of abuse, especially in infants [10]. The main features of fractures suggestive of child abuse are summarized in Table 1. First step in the evaluation of a child presenting with fracture: careful history and clinical examination. Suspicion of physical abuse should be reasonably excluded in an otherwise healthy child with a fracture caused by reported non-accidental injury. Suspicion of bone fragility should be considered when a non-accidental injury occurs in a child with underlying health condition predisposing to bone fragility. However, accidental injury may also affect an unhealthy child. 1One or more; 2presence of signs or symptoms known to be associated with bone fragility Table 1Main features of fractures that may be associated with child abuse• No history of injury• History of injury not plausible1• Inconsistent histories or changing histories provided by parents/caregivers• Fracture in a no ambulatory child• Fracture of high suspicion for child abuse (e.g., fracture of rib, scapula, sternum)• Multiple fractures• Fractures of different ages and/or stages of healing• Delay in seeking care for an injury• Bruising in unusual body locations (e.g., ears, neck, or trunk)2• Absence of clinical signs of medical conditions associated with bone fragility• Other injuries raising suspicion for child abuse1Mechanism causing fracture inconsistent with the type of fracture, the energy load needed to cause the fracture, or the severity of the injury2Raises concern for child abuse and needs further evaluationFrom Ref. [10], mod Main features of fractures that may be associated with child abuse 1Mechanism causing fracture inconsistent with the type of fracture, the energy load needed to cause the fracture, or the severity of the injury 2Raises concern for child abuse and needs further evaluation From Ref. [10], mod If a child presents clinical features typically associated with bone fragility, a non-accidental fracture should prompt further evaluation for an underlying skeletal disorder (Table 2). In patients with signs attributable to bone fragility, the threshold for initiating a bone health evaluation should be lower than in the absence of such features [6]. Table 2Main clinical signs and history suggestive of a fragility fracture disorder• Short stature, especially if associated with body disproportion• Plagiocephaly• Facial dysmorphisms• Rib cage deformities• Blue/gray sclerae• Skin laxity• Joint hypermobility• Scoliosis• Skeletal deformities• Dental abnormalities (enamel and/or dentin defects) or premature teeth loss (with intact roots)• Wormian bones• Abnormal waddling gait• Bone and joint pain• Easy bruising• Positive family history of osteoporosis/osteogenesis imperfecta• Other signs possibly associated with a fragility fracture disorder Main clinical signs and history suggestive of a fragility fracture disorder The skeletal site of the fracture may also provide important diagnostic information. Low-trauma fractures involving vertebrae, femur, humerus, or flat bones strongly support the need for immediate bone health assessment. Conversely, fractures occurring in other skeletal sites, such as radius, ulna, tibia, fibula, bones of the hand or foot, or clavicle, require additional supporting evidence before initiating a comprehensive bone health work-up [6]. Laboratory investigations Measurement of some blood and urinary biochemical parameters is useful for excluding vitamin D deficiency rickets, genetic forms of rickets, hypophosphatasia (HPP), and for assessing secondary causes of osteoporosis. Laboratory tests should be tailored to clinical suspicion; random or untargeted tests are not recommended. Suggested laboratory investigations in a child with suspected osteoporosis are summarized in Table 3. Table 3Biochemical measurements suggested in children and adolescents with suspected osteoporosisBlood tests• ESR and complete blood cell count• Calcium, phosphate, magnesium, alkaline phosphatase (bone-specific alkaline phosphatase isoenzyme if available), intact parathyroid hormone (second- or third-generation generation), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D• Creatinine, total proteins and serum protein immunoelectrophoresis• Immunoglobulins, anti-tissue transglutaminase IgA• Biochemical markers of bone turnover1• Additional tests based on the diagnostic suspicionUrine tests• Calcium/creatinine ratio (spot sample)• Biochemical markers of bone turnover2• Additional tests based on the diagnostic suspicion1Osteocalcin, procollagen type I N-propeptide (PINP), and C-telopeptides of type I collagen (CTX)2Urinary N-telopeptides of type I collagen (uNTx)Nota bene: interpretation of biochemical markers of bone turnover in children and adolescents may be challenging due to the wide reference ranges and the influence of age, sex, linear growth, and pubertal stage Biochemical measurements suggested in children and adolescents with suspected osteoporosis 1Osteocalcin, procollagen type I N-propeptide (PINP), and C-telopeptides of type I collagen (CTX) 2Urinary N-telopeptides of type I collagen (uNTx) Nota bene: interpretation of biochemical markers of bone turnover in children and adolescents may be challenging due to the wide reference ranges and the influence of age, sex, linear growth, and pubertal stage Radiographic and bone densitometry assessment Radiographic examination is useful for assessing the fracture features and the overall bone structure. Reduced cortical thickness and loss of bony trabeculae may indicate a reduced bone mineral content [11]. Radiographs are also essential for detecting and grading vertebral fractures and scoliosis. As in adults, early X-ray signs of vertebral fracture include > 20% reduction in vertebral height ratio, loss of endplate parallelism, endplate interruption or anterior cortical buckling [9]. Unlike adult guidelines, where back pain alone does not represent an indication to perform imaging, lateral spine imaging (thoracic and lumbar vertebrae) should be performed in all children and adolescents with suspected osteoporosis, and hidden vertebral fractures should be investigated [12]. In addition to the site of the fracture, radiographic assessment can be extended to other skeletal sites according to clinical findings and diagnostic suspicion. Dual energy X-ray absorptiometry (DXA) is the most widely used method for assessing BMD in children and adolescents and is part of a comprehensive skeletal health assessment in patients at increased risk of fracture [8, 12–14]. Lumbar spine and total body less head (TBLH) are the preferred BMD measurement sites in children and adolescents. ISCD recommendations for DXA assessment, interpretation, and reporting in children and adolescents with disorders affecting the skeleton are summarized in Table 4. A major limitation of DXA measurements in growing children is that it is influenced by skeletal growth and bone size [15]. Some methods have been proposed for reducing these limitations, such as the use of some mathematical formulas extrapolating new parameters named bone mineral apparent density (BMAD) or volumetric bone mineral density (vBMD) [16, 17], or the adjustement of BMD for height Z-score [18]. Although correction of BMD for the extrapolated bone volume may reduce the confounding effect of bone size, vBMD remains age- and bone size-dependent during skeletal growth [19]. Table 4DXA assessment, interpretation, and reporting in children and adolescents with skeletal disorders by ISCDDXA assessment• In patients with primary bone disease, or at risk for a secondary bone disease, a DXA measurement should be performed when the patient may benefit from interventions to decrease their elevated risk of a clinically significant fracture, and the DXA results will influence that management• DXA should not be performed if safe and appropriate positioning of the child cannot be ensured.• DXA should not be performed if the child cannot remain still• The diagnosis of osteoporosis in children and adolescents should not be based solely on densitometric criteria alone• DXA is the preferred method for assessing BMC and areal BMD• The PA spine and TBLH are the preferred skeletal sites for measuring BMC and areal BMD in most pediatric subjects• DXA-based VFA may be used as a substitute for spine radiography to identify symptomatic and asymptomatic vertebral fracture• The Genant semiquantitative method [9] should be used for VFA in children• After VFA, additional spine imaging should be considered in the following circumstances: a) if vertebrae are not adequately visible during VFA, and detecting a vertebral fracture would influence clinical management; b) assessment of a single, Genant Grade 1 VF, if confirmation of a Grade 1 VF alone would change clinical management; c) radiographic findings that are not typical for an osteoporotic VF (e.g. suspected destructive inflammatory or malignant processes, congenital malformations, acquired misalignments or dislocations)• Soft tissue assessment in conjunction with whole-body scans may be helpful in evaluating patients with chronic conditions associated with malnutrition or muscle and skeletal deficits• Proximal femur DXA measurements can be used, if appropriate reference data are available, for assessing adolescents with reduced weight bearing and mechanical loading of the lower extremities or in adolescents at-risk for bone fragility who would benefit from continuity of DXA measurements through the transition into adulthood. However, DXA measurements may be influenced by anatomical changes of proximal femur related to skeletal growth or the occurrence of proximal femur malformations (e.g. coxa-vara/coxa valga)• DXA measurements at the 33% radius (1/3 radius) may be used in children who cannot be scanned at other skeletal sites, provided adequate reference data are available• If a follow-up DXA scan is indicated, the minimum interval between scans is 12 monthsDXA interpretation• An appropriate reference data set must include a sample of healthy representatives of the general population sufficiently large to capture variability in bone measures that takes into consideration gender, age, and race/ethnicity• In children with short stature or growth delay, spine and TBLH BMC and areal BMD results should be adjusted. For the spine, adjust using either BMAD or height Z-score. For TBLH, adjust using height Z-score• DXA lumbar spine measurements are feasible and can provide reproducible measures of BMC and areal BMD for infants and young children 0-5 years of age• DXA whole body measurements are feasible and can provide reproducible measures of BMC and areal BMD for children ≥ 3 years of age• Below 5 years of age the impact of growth delay on DXA measurements cannot be reliably quantified• Serial DXA reports should include the same information as for baseline testing. Additionally, indications for follow-up scan; technical comparability of studies; changes in height and weight; and change in BMC and areal BMD Z-scores should be reportedAbbreviations: DXA, Dual energy X-ray absorptiometry; ISCD: International Society of Clinical Densitometry; BMC, bone mineral content; BMD, bone mineral density; PA, posterior-anterior; TBLH, total body less head; VFA, vertebral fracture assessment; BMAD, bone mineral apparent densityNota bene: for additional information and more details visit https://iscd.org/learn/official-positions/pediatric-positions/From Ref. [8], mod DXA assessment, interpretation, and reporting in children and adolescents with skeletal disorders by ISCD • DXA should not be performed if safe and appropriate positioning of the child cannot be ensured. • DXA should not be performed if the child cannot remain still Abbreviations: DXA, Dual energy X-ray absorptiometry; ISCD: International Society of Clinical Densitometry; BMC, bone mineral content; BMD, bone mineral density; PA, posterior-anterior; TBLH, total body less head; VFA, vertebral fracture assessment; BMAD, bone mineral apparent density Nota bene: for additional information and more details visit https://iscd.org/learn/official-positions/pediatric-positions/ From Ref. [8], mod Peripheral quantitative computed tomography (pQCT) at radius and tibia can be used to assess bone density in children and adolescents, but expertise and appropriate reference data should be available [12, 20]. Quantitative ultrasound (QUS) techniques may be useful tools to assess integral bone mineral status and fracture risk in children as a complementary method to DXA if expertise and appropriate reference data are available [21–23]. However, stand-alone QUS is not recommended for treatment initiation decision-making or follow-up in children and adolescents. The only validated skeletal site for the clinical use of QUS in osteoporosis management is the heel in postmenopausal women and men over 65 [8]. Nonetheless, QUS methods may be useful to assess bone mineral status when DXA assessment is not feasible, especially in infants and children younger than 4-5 years, due to difficulty in appropriate positioning, high risk of movement artefacts, and to avoid sedation. Genetic analysis Genetic testing in patients with bone fragility is typically based on DNA sequencing, using either with targeted gene panels or whole-exome analysis. However, gene panels used in clinical practice often encompass a limited selection of genes and may not be current, given the rapidly evolving landscape of monogenic osteoporosis. The most recent update of Nosology of Genetic Skeletal Disorders includes the main genes and disorders associated with fragility fractures/osteoporosis; this classification may assist clinicians in assessing the differential diagnosis, guiding bioinformatic analysis of next-generation sequencing results, and providing a framework for advances in bone biology, genetic, and precision medicine [24]. Some experts recommend starting with the analysis of the most frequently implicated genes (e.g. type I collagen genes, PLS3, LRP5, and others) and proceeding to whole-exome/genome sequencing if results are negative. Other bone specialists advocate for direct whole-exome analysis, but high costs may limit this approach. Despite advances in sequencing technologies, a substantial proportion of patients remain undiagnosed after exome analysis. If exome sequencing is unrevealing, additional technologies may be considered, including genome sequencing, single-cell or long-read transcriptomics, methylation profiling, metabolomics, and proteomics [25]; nevertheless, these approaches are not widely applicable in routine clinical practice. Currently, there is no standardized approach to genetic testing, and each pediatric osteology center may adopt its own gene panel, with different threshold for genetic. We recommend testing as many clinically relevant genes as feasible followed by whole-exome analysis if targeted panels are negative. Genetic testing remains the definitive method to confirm the diagnosis in patients with primary osteoporosis. As suggested by Ward [6], a low threshold for genetic testing should be maintained in children and adolescents with suspected monogenic conditions of bone fragility to reduce misclassification as non-accidental injury or idiopathic osteoporosis. Furthermore, re-assessing genetic analyses during follow-up should be considered in patients with undiagnosed bone fragility in light of emerging knowledge [26, 27]. Bone biopsy When the diagnosis remains uncertain, bicortical transiliac bone biopsy represents the definitive method for assessing bone density, turnover, and microarchitecture [5]. Bone biopsy can be also helpful in differentiating low-turnover from high-turnover osteoporosis, and in detecting osteomalacia. Nevertheless, given its invasive nature, bone biopsy should be reserved for selected children and adolescents with severe osteoporosis and fragility fractures of unknown etiology, and it should be performed in experienced centers. Statement 3. Diagnosis of osteoporosis in children and adolescents should be based on family and medical history, clinical examination, laboratory investigations, radiographic and bone densitometry assessment, and genetic testing. Statement 4. Extended genetic testing is recommended in children and adolescents with suspected primary osteoporosis. Statement 5. Additional genetic testing should be considered during follow-up in children and adolescents with undiagnosed bone fragility in accordance with the most recent scientific evidence. Main causes of primary and secondary osteoporosis In the diagnostic work-up of children and adolescents with fragility fractures it is crucial to identify the underlying etiology, as prognosis and treatment may vary markedly according to the cause. The first step is to differentiate between primary and secondary forms of osteoporosis. Although many secondary causes of osteoporosis should be considered, most of them may be readily diagnosed or excluded through careful medical history, clinical examination, and laboratory investigations. Since primary and secondary osteoporosis can coexist, both diagnoses should be considered even when one appears more likely [6]. Primary osteoporosis Osteogenesis imperfecta (OI) is the most well-known genetic disorder associated with bone fragility and, especially in its mild forms, may be challenging to differentiate from other forms of primary osteoporosis. Mutations in COL1A1 and COL1A2 account for approximatey 85-90% of patients with OI [28]. However, several additional genes involved in collagen biosynthesis, bone mineralization, and osteoblast differentiation have been identified as causative of both OI and other forms of primary osteoporosis, thereby expanding the molecular mechanisms of bone fragility [28]. The 2023 revised Nosology of Genetic Skeletal Disorders included over 50 genetic conditions within the "Osteogenesis imperfecta and bone fragility group" [24]. In children with a suspected form of primary osteoporosis, detailed clinical and biochemical characterization remains crucial for establishing a correct diagnosis. Genetic testing is recommended, particularly when the disease manifests at an early age or when there is a family history of osteoporosis [29]. Genes implicated in various forms of OI due to abnormalities in primary or secondary type I collagen function, and mechanisms underlying the altered structure of type I collagen [6, 12] are summarized in Table 5. The current genetic classification describes 23 OI types. Some forms result from indirect collagen-related mechanism involving osteoblast development. Moreover, certain forms of primary osteoporosis are caused by mutations in genes unrelated to OI, including some skeletal dysplasias, skin laxity, especially Ehlers-Danlos syndromes, tall stature, vascular calcification, spinal muscular atrophy, or other mutations associated with a mild phenotype (Table 6). These distinguishing features may be useful for the diagnosis, even though in some circumstances clinical signs may be mild and BMD values may be normal [30]. Table 5Genes implicated in various forms of osteogenesis imperfecta and mechanisms underlying altered type I collagen structurePrimary defects in collagen structure or processingDefects of collagen modificationsDefect of collagen folding and cross-linkingDefects of ossification or mineralizationDefects in osteoblast development (secondary collagen insufficiency)COL1A1 - COL1A2 OI 1-4CRTAP OI 7SERP1NH1 OI 10IFITM5 OI 5WNT1 OI 15BMP1 OI 13LEPRE1 OI 8FKBP10 OI 11 BS 1SERPINF1 OI 6CREB3L1 OI 16SPARC OI 17PPIB OI 9PLOD2 BS 2SGMS2 CDL/CDLSMDSP7 OI 12TENT5A (FAM46A) OI 18TMEM38B OI 14P4HB CCS 1MESD OI 20MBTPS2 OI 19SEC24D CCS 2LRP5 OPGKDELR2 OI 21PHLDB1 OI 23CCDC134 OI 22FGFR2 EOOPSEC24D CCS 2Abbreviations: BS: Bruck syndrome; CCS: Cole-Carpenter syndrome; CDL: Calvarial Doughnut Lesions syndrome with bone fragility with or without spondylometaphyseal dysplasia (SMD); EOOP: early-onset osteoporosis; OI: osteogenesis imperfecta OPG: osteoporosis pseudoglioma syndromeFrom Ref. [6], mod Genes implicated in various forms of osteogenesis imperfecta and mechanisms underlying altered type I collagen structure Abbreviations: BS: Bruck syndrome; CCS: Cole-Carpenter syndrome; CDL: Calvarial Doughnut Lesions syndrome with bone fragility with or without spondylometaphyseal dysplasia (SMD); EOOP: early-onset osteoporosis; OI: osteogenesis imperfecta OPG: osteoporosis pseudoglioma syndrome From Ref. [6], mod Table 6Primary osteoporosis and related genes implicated in disorders not related to osteogenesis imperfectaSkeletal dysplasiasSkin laxity disordersTall stature syndromesSMABFVascular calcificationsOtherSpondilo-ocular dysplasia (XYLT2)Geroderma osteodysplasticum (GORAB)Marfan syndrome (FBN1)SMABF1 (TRIP4)Singleton-Merten dysplasia 1 (IFIH1)Osteoporosis AD form, ARHGAP25‐related(ARHGAP25)Gnatho-diaphyseal dysplasia (ANO5)Cutis laxa type 2B (PYCR1)Loeys-Dietz syndrome2SMABF2 (ASCC1)Singleton-Merten dysplasia 2 (DDX58)Cleidocranial dysplasia (RUNX2)Ehlers-Danlos syndromes1Homocystinuria (CBS)Larsen syndrome3 (B3GAT3)Snyder-Robinson syndrome (SMS)Osteoporosis with developmental delay and microcephaly (COPB2)Abbreviations: SMABF, spinal muscular atrophy with congenital bone fractures1Multiple genes are involved in the various forms of Ehlers-Danlos syndrome, including COL1A12Osteopenia with increased frature risk may be observed in all variants of the Loeys‐Dietz syndrome (TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, SMAD3)3OMIM #245600From Ref. [6], mod Primary osteoporosis and related genes implicated in disorders not related to osteogenesis imperfecta Osteoporosis AD form, ARHGAP25‐related (ARHGAP25) Abbreviations: SMABF, spinal muscular atrophy with congenital bone fractures 1Multiple genes are involved in the various forms of Ehlers-Danlos syndrome, including COL1A1 2Osteopenia with increased frature risk may be observed in all variants of the Loeys‐Dietz syndrome (TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, SMAD3) 3OMIM #245600 From Ref. [6], mod However, in some patients the cause of primary osteoporosis remains unidentified, so that it may be considered as idiopathic. Ongoing advances in genetic knowledge and expanded genetic testing are expected to reduce the proportion of the idiopathic forms of primary osteoporosis. Secondary osteoporosis A secondary cause of osteoporosis can be identified in a substantial proportion of pediatric subjects [31]. Secondary osteoporosis may arise as a complication of many conditions, including endocrinopathies, gastrointestinal or inflammatory disorders, haematologic diseases, neuromuscular disorders, and lysosomal storage diseases [5, 32–36]. The pathogenesis of secondary osteoporosis varies according to the underlying condition, but in most disorders is multifactorial. Secondary osteoporosis may also be iatrogenic, particularly as a consequence of prolonged glucocorticoid treatment for various medical conditions [37, 38]. The main causes of secondary osteoporosis in pediatric patients are listed in Table 7. Table 7Main causes of secondary osteoporosis in children and adolescentsEndocrinopathiesGastrointestinal disordersInflammatory disordersHypogonadism (hyper-and hypogonadotropic)Inflammatory bowel diseaseSystemic vasculitisHyperthyroidismCeliac diseaseJuvenile idiopathic arthritisHyperparathyroidismCystic fibrosisJuvenile dermatomyositisHypercortisolismBiliary AtresiaSystemic lupus erythematosusGrowth hormone deficiencyChronic liver diseaseMixed connective tissue diseaseAmenorrea due to anorexia nervosaTotal parenteral nutritionDiabetes mellitusShort bowel syndromeHaematologic diseasesIatrogenicOthersThalassemia majorGlucocorticoidsProlonged immobilizationLeukemiaMethotrexateGaucher’s diseaseLymphomaCyclosporinGlycogen storage diseaseCongenital haemolytic anemiasHeparinMucopolysaccharidosesHaemophiliaAnti-retroviral agentsFabry diseaseBone marrow/stem cell/solid organ transplantTacrolimusCerebral palsySystemic mastocytosisAnticonvulsants1Neuromuscular diseasesHereditary haemochromatosisLevothyroxine excessSevere reduction in calcium/vitamin D intakeMastocytosisProton pump inhibitorsHIV infectionRadiation therapyChronic renal failure1Phenytoin, phenobarbital, valproic acid, and carbamazepine Main causes of secondary osteoporosis in children and adolescents 1Phenytoin, phenobarbital, valproic acid, and carbamazepine Laboratory testing has a central role in the evaluation of children with a suspected secondary form of osteoporosis and it should be guided by history and clinical findings. Additional investigations, such as bone marrow aspiration, imaging techniques, endoscopy, colonoscopy, tissue biopsies, blood and urinary biomarkers, genetic testing, or other targeted investigations, should be performed when clinically indicated. Importantly, children and adolescents with a fragility fracture should be assessed for secondary causes even in the absence of a low BMD Z-score [36]. Diagnostic algorithm in children and adolescents with suspected osteoporosis Diagnostic guidelines of osteoporosis in children and adolescents differ from those recommended in adults. Most pediatric osteology centers adopt their own structured approach to children with a fragility fracture. The diagnostic work-up includes clinical history, physical examination, laboratory investigations, radiographic assessments, and BMD measurements. The extent of laboratory testing may vary between centers. Whenever possible, children with a history of fragility fractures should undergo bone densitometry investigation [5, 8]. In all cases, the diagnostic work-up should consider the mechanism of injury, fracture site, severity and number of fractures, and the presence of potential risk factors. Before considering that the child may be affected by a primary or secondary osteoporosis, all forms of rickets (including the genetic conditions) and HPP should be ruled out [6]. Unless clinical findings strongly suggest primary osteoporosis (Table 2), secondary causes and treatment associated with increased risk of fracture should be investigated. Once secondary causes and comorbidities have been excluded, genetic testing should be considered to assess the possibility of an underlying monogenic cause of osteoporosis. Figure 2 shows a proposed algorithm for the diagnostic work-up in children and adolescents with suspected osteoporosis. If genetic testing is negative, osteoporosis should be considered as idiopathic. Algorithm outlining the diagnostic workup in children and adolescents with suspected primary or secondary osteoporosis. Three primary steps, including familial and medical history, physical examination, laboratory investigations, and X-ray and bone densitometry evaluations, are required to assess whether the child of the adolescent may have a disorder of mineral metabolism or a secondary form of osteoporosis. If a disorder of mineral metabolism is excluded, a primary or secondary form of osteoporosis should be considered. If a secondary form of osteoporosis is suspected, the underlying cause must be identified. If a secondary form of osteoporosis is excluded and a primary form of osteoporosis is suspected, genetic testing should be performed. Negative genetic testing do not exclude a primary form of osteoporosis. 1According to ISCD recommendations [8]. 2Sanger sequencing, next generation sequencing, whole-exome sequencing, whole-genome sequencing. 3If the genetic testing are negative, the diagnosis should be re-evaluated during follow-up in the light of new evidence that arises Statement 6. All forms of rickets, HPP, and non-accidental fractures should be excluded before considering that the child is affected by a primary or secondary osteoporosis. Statement 7. Genetic testing is recommended in children with suspected primary osteoporosis and in those with a family history of osteoporosis. Statement 8. Secondary osteoporosis should be considered in all children and adolescents with conditions known to be associated with fragility fractures. Statement 9. All children and adolescents with fragility fractures should be evaluated for primary or secondary osteoporosis, even in the absence of a low BMD Z-score. Statement 10. If genetic testing is negative, osteoporosis should be considered as idiopathic. Evaluation of the potential for spontaneous or bisphosphonate-induced recovery from bone fragility Following a diagnosis of fragility fracture resulting from either primary or secondary osteoporosis, bisphosphonate treatment may be considered. Bisphosphonates are the mainstay of pharmacological intervention in children and adolescents with bone fragility due to primary or secondary osteoporosis [6, 32, 39–43]. However, the diagnosis of osteoporosis in children does not necessarily require the need to treat [6]. Indeed, growing children may have the potential to undergo spontaneous (i.e. medication-unassisted) recovery from a vertebral fracture, obviating the need for osteoporosis drug therapy [6, 44]. Unlike adults, the pediatric skeleton is driven to undergo bone mass restitution and to reshape previously fractured vertebral bodies. Vertebral body reshaping results from skeletal modeling linked to activity at the vertebral growth plate (known as vertebral "catch-up growth"), as long as the child’s risk factors are temporary and there is adequate residual growth potential [6]. Vertebral fracture reshaping has also been observed in patients with OI undergoing intravenous bisphosphonate treatment [45–47], as well as in some patients affected by rare syndromes associated with bone fragility [48, 49]. However, spontaneous vertebral reshaping may occur only in certain secondary forms of osteoporosis [6, 44]. A recent study in glucocorticoid-treated children with leukemia, rheumatic disorders, or nephrotic syndrome showed that more than 80% of patients achieved complete spontaneous vertebral body reshaping over six years, without bisphosphonate treatment [50]. The median time to full vertebral reshaping was 1.3 years, and vertebrae with the highest vertebral fracture rates were those most likely to reclaim normal vertebral dimensions [50]. Similar findings were reported by the STOPP Consortium in a longitudinal study in children with leukemia [7]. Conversely, children and adolescents with Duchenne muscular dystrophy (DMD) generally do not demonstrate spontaneous vertebral body reshaping or complete recovery of BMD [51]. A systematic review identified only three studies reporting partial or complete vertebral body reshaping in children with DMD treated with bisphosphonate, whereas reshaping was not observed in untreated patients [52]. Nasomyont et al. [53] reported that 33% of patients with DMD with residual growth potential receiving oral alendronate had complete vertebral body reshaping. However, bisphosphonate treatment did not prevent the occurrence of new vertebral fractures in some patients with DMD [54]. Furthermore, it has been shown that even with early bisphosphonate treatment bone health deficits persisted, including reduced long bone cross-sectional diameter and progressive vertebral collapse despite normal lumbar spine BMD Z-scores [38]. A recent study demonstrated that combined treatment with recombinant growth hormone, testosterone, and zoledronate was more effective than zoledronate alone in promoting vertebral reshaping [54]. These findings suggest that persistence of risk factors for osteoporosis, such as progressive myopathy, loss of ambulation, delayed puberty, and ongoing glucocorticoid treatment may affect the reshaping of the vertebral body and periosteal/endosteal modeling. A Workshop Report has proposed a pro-active approach in children with DMD before the occurrence of the first fracture; however, criteria for its implementation are not yet well established [55]. Some factors may influence the spontaneous reshaping of vertebral body and recovery of BMD, thereby obviating or delaying bisphosphonate treatment. Figure 3 outlines a proposed approach to assess the child’s likelihood of spontaneous recovery of vertebral fracture [6, 38, 50]. Key determinants affecting the spontaneous reshaping phenomenon include persistence of the risk factors for osteoporosis, glucocorticoid treatment, age, severity of vertebral collapse, fracture progression, and reduced mobility. In addition to the potential for vertebral reshaping, the occurrence of new long bone fractures should also be considered to plan bisphosphonate treatment. The spinal deformity index (SDI), which integrates the number and severity of vertebral fracture from T4 to L4, may provide a useful measure of overall fracture burden in adults [9, 56] and children [50]. Proposed approach to assess the child’s ability to undergo spontaneous recovery of vertebral fracture based on the estimation of the chance of recovery. *According to Genant-defined severity grades of vertebral fracture; mild fracture grade corresponds to a vertebral height ratio loss >20% and <25% [9]. SDI: spinal deformity index, defined as the sum of grades from T4 to L4 [9, 50, 56]. Adapted and modified from Ref. [6] Data on spontaneous vertebral reshaping in children and adolescents with fragility fractures related to primary osteoporosis are limited. An isolated case of spontaneous vertebral reshaping has been reported in an adolescent with OI with mild-to-moderate vertebral collapse [57]. However, this uncommon possibility should not delay bisphosphonate treatment in patients with OI or other forms of primary osteoporosis. Decision-making for bisphosphonate treatment in patients with bone fragility and absence of vertebral compression (crush) fractures According to ISCD criteria [8], in children and adolescents without vertebral compression fractures the diagnosis of osteoporosis may be established by a clinically significant history of long bones low-trauma fracture ( ≥ 2 low-trauma fractures by age 10 years or ≥ 3 low-trauma fractures at any age up to 19 years) in combination with a reduced (≤ -2.0) BMD Z-score adjusted for bone size. Therefore, careful evaluation of fracture site, mechanism, and context is therefore essential for diagnosing osteoporosis in children and adolescents without vertebral compression fractures. In some patients, long bones low-trauma fractures may precede the occurrence of vertebral compression fractures. However, ISCD criteria could be overly restrictive in children and adolescents with an elevated risk of osteoporotic fractures, such as those receiving long-term and/or high-dose of glucocorticoid therapy (e.g. DMD and leukemia) [35] or those affected by primary forms of osteoporosis, such as OI or other skeletal dysplasias associated with bone fragility [58]. Indeed, it has been recognized that other features of the fracture and its clinical context should be considered, and even a single long bone low-trauma fracture may represent a major osteoporotic event [35]. Lower extremity fractures are frequent in glucocorticoid-naïve boys with DMD, occurring in up to 40% [35], with doubling of the fracture risk in the presence of glucocorticoid treatment [59]. In children and adolescents with leukemia, long bone low-trauma fractures have been reported in 23% over the five years following diagnosis, with no new fractures between five and six years [7]. Comminuted fractures, and fractures with atypical displacement, can be particularly concerning, especially when there is no accompanying trauma [35]. Non-vertebral fractures outside the long bones (e.g., fingers, toes) are not typically considered sufficient to justify bisphosphonate therapy. Nevertheless, even apparent minor fractures should prompt a careful assessment [35]. Therefore, children and adolescents with low-trauma long bones fragility fractures should be carefully investigated in accordance with ISDC criteria [8], and bisphosphonate treatment should be considered. Children and adolescents who do not fully meet ISCD criteria [8], such as those presenting with a first low-trauma fracture or with a normal BMD Z-score, should undergo close longitudinal follow-up as additional low-trauma long bone or vertebral compression fractures may occur over time, even much further away from the first low-trauma fracture. Statement 11. Spontaneous reshaping of the vertebral bodies should be taken into consideration before planning bisphosphonate treatment in children and adolescents with a vertebral fracture due to secondary osteoporosis. Statement 12. Spontaneous reshaping of the vertebral bodies does not usually occur in children and adolescents with vertebral fracture due to primary osteoporosis, but it may occur during bisphosphonate treatment. Statement 13. Bisphosphonate treatment should be planned in children and adolescents with primary or secondary osteoporosis with ≥ 2 low-trauma long bone fractures by age 10 years or ≥ 3 low-trauma long bone fractures by age 19 years, even in absence of vertebral fractures and despite a normal BMD Z-score. Statement 14. Children and adolescents who do not fully meet ISCD criteria (e.g. only one low-trauma long bone fracture by age 10 years or ≤ 3 low-trauma long bone fractures by age 19 years) should undergo long-term follow-up to monitor for additional low-trauma bone fractures. Management of bisphosphonate treatment Experience in treating patients with OI has provided the starting point for the bisphosphonate treatment of children and adolescents with fragility fractures, whereas few data are available for patients with other forms of primary osteoporosis. The most used bisphosphonates worldwide (Europe, the Americas, and the Asia-Pacific region) are intravenous pamidronate and zoledronate, and oral alendronate and risedronate [43]. Treatment is typically started using intravenous formulations. Some centers begin with pamidronate in infants and young children and subsequently switch to zoledronate, while others use zoledronate from the onset [43]. Dosing regimens for the main intravenous bisphosphonates used in pediatric patients with osteoporosis are summarized in Table 8. Oral bisphosphonates are generally reserved for patients with mild-to-moderate OI in the absence of vertebral compression fractures [39]. The usual dose is 1-2 mg/kg/week (maximum 70 mg/week) for alendronate and 15 mg/week in patients weighing < 40 kg, and 30 mg/week in those weighing > 40 kg for risedronate [60]. Table 8Dosing regimens of the main intravenous bisphosphonates used in pediatric patients with osteoporosisBisphosphonateAge, yearsDosage, mg/Kg/dayCycle intervalPamidronate1< 20.5 for 3 days6-8 weeks2-50.75 for 3 days2-3 months> 51.0 for 3 days3-4 monthsMaintenance3 mg/Kg/yearIn 2 divided dosesNeridronate2< 21 mg/Kg/day for 2 days3 months> 22 mg/Kg/day for 1 day3 monthsMaintenanceNDNDZoledronate3< 20.023 months2-50.0354 months> 50.056 monthsMaintenance0.025 mg/Kg/year12 monthsAbbreviations: ND, not defined1Diluted in 200-250 ml isotonic saline solution (0.1 mg/mL), at least in 3 hours. Maximum total daily dosage 60 mg2Diluted in 200-250 ml isotonic saline solution (0.1 mg/mL), at least in 3 hours. Maximum total daily dosage 100 mg3Diluted in 50 ml isotonic saline solution 30-60 min. Maximum total daily dosage 4 mg Dosing regimens of the main intravenous bisphosphonates used in pediatric patients with osteoporosis Abbreviations: ND, not defined 1Diluted in 200-250 ml isotonic saline solution (0.1 mg/mL), at least in 3 hours. Maximum total daily dosage 60 mg 2Diluted in 200-250 ml isotonic saline solution (0.1 mg/mL), at least in 3 hours. Maximum total daily dosage 100 mg 3Diluted in 50 ml isotonic saline solution 30-60 min. Maximum total daily dosage 4 mg Despite over thirty years of pediatric experience with the use of bisphosphonates, all of which is off-label with the exception for neridronate in patients with OI in Italy, no consensus has been reached regarding the most effective bisphosphonate, optimal dosing regimen, or route of administration; thereby, treatment approaches may vary depending on the expertise of clinicians [39, 43]. In patients with DMD, the more favorable outcomes have been reported with intravenous zoledronate [52]. In patients with OI, among the various bisphosphonates (neridronate not included), pamidronate has shown greater improvements in lumbar areal BMD, whereas zoledronate has achieved the largest gains in BMD Z-score but with more adverse events. Neither of them significantly reduced fracture rates over 2-year treatment period. Conversely, olpadronate was the only treatment that demonstrated a significant reduction in annualized total fracture numbers compared to placebo, with a weighted mean difference of -1.65 (95% CI -3.05, -0.26; CoE, moderate) over two years. Overall, current evidence remains insufficient to identify the most effective bisphosphonate for reducing fracture rate in patients with OI [61]. Currently, no international guidelines for bisphosphonate treatment in pediatric patients are available. Factors typically considered to plan bisphosphonate treatment in children and adolescents with fragility fractures include early fractures onset, poor potential for spontaneous recovery (in secondary osteoporosis), disease severity, and impaired quality of life (QoL), including back pain, bone pain, and reduced mobility [6, 39, 60, 62–65]. A proposed algorithm outlining the main criteria for bisphosphonates treatment in pediatric patients with fragility fractures due to primary or secondary osteoporosis is presented in Fig. 4. Proposed algorithm for bisphosphonate treatment in children and adolescents with fragility fractures due to primary or secondary osteoporosis. Bisphosphonate treatment is indicated in patients with low potential for spontaneous recovery related to age (≥ 8 years in girls or ≥ 9 years in boys), irrespective of risk factors; in younger patients with persistent risk factors for secondary osteoporosis; in infants with fractures occurring within the first six months of life, including in utero and perinatal fractures; in patients with primary or secondary osteoporosis when fractures have a significant impact on quality of life. Bisphosphonate treatment is not indicated in the absence of fragility fractures; however, careful monitoring of risk factors resolution and achievement of complete recovery is recommended. Optimization of bone health is advised in all patients, regardless of the presence of fragility fractures. *Depending on the underlying disease; in patients with neuromuscular disorders this target cannot be achievable. If stabilization of osteoporosis is achieved the initial dosing regimen of bisphosphonate may be reduced to maintenance doses. If stabilization of osteoporosis in not achieved bisphosphonate treatment should be continued at the initial dosing regimen. Adapted and modified from refs. 6, 36, 39, 65, and authors’ expertise Although there is no consensus on whether any method of reduction is safer or more effective, titration of bisphosphonate dose should be considered once stabilization of osteoporosis has been achieved. Generally, bisphosphonate treatment is continued until final height, unless evidence of intolerance or severe adverse reactions [6, 43, 60, 63]. Discontinuation of treatment before epiphyseal fusion may result in newly formed bone having reduced mineral density compared to bone accrued during the treatment period, with the consequent risk of fractures at the interface between the "old" and "new" bone [66]. Nevertheless, no recommendations on the duration of bisphosphonate treatment are imposed. In adult patients at low fracture risk discontinuation of bisphosphonate may be considered after 5 years of treatment [67]; no official recommendation for discontinuation of bisphosphonate treatment is currently available for pediatric patients. Bisphosphonate treatment during transition During transition to young adulthood, bisphosphonate treatment is usually discontinued in some centers, with periodic re-assessment (typically every six months or more frequently if clinically indicated). Some centers adopt a gradual dose-reduction ("weaning off" regimen), whereas others recommend a switch from intravenous to oral treatment [43, 60]. In patients affected by severe forms of OI bisphosphonate treatment is usually continued without interruption. In some patients who experience severe musculoskeletal pain and/or fatigue after some months of suspension, bisphosphonate treatment may be resumed, irrespective of the occurrence of new fractures [43]. These considerations highlight the lack of standardized recommendations for bisphosphonate management during transition to adulthood. We suggest that decision regarding continuation of bisphosphonate treatment during transition should be individualized and based on disease severity, including occurrence of new fragility fractures and any deterioration in QoL, regardless of whether new fractures occur. The transition from pediatric to adult care in individuals with primary osteoporosis may be complex and requires a structured patient-centered approach. In patients with OI a structured five‐step transition model has been proposed to ensure a seamless transition, benefiting patients, their families, and caregivers [68]. Statement 15. Intravenous bisphosphonates represent the standard of care for children and adolescents with fragility fractures. Statement 16. Current evidence does not support the superiority of any specific bisphosphonate for pediatric patients with fragility fractures. Statement 17. Bisphosphonate treatment should be planned in children and adolescents with early onset fractures, poor potential for spontaneous recovery (in secondary osteoporosis), severe disease, and impaired QoL. Statement 18. Titration of bisphosphonate dose should be considered once stabilization of osteoporosis has been achieved. Statement 19. During transition to adulthood, bisphosphonate treatment should be continued without interruption in patients with severe forms of OI and may be resumed in patients experiencing significant musculoskeletal pain and/or fatigue after treatment discontinuation, irrespective of new fracture occurrence. Adverse effects during bisphosphonate treatment Bisphosphonate treatment is generally well tolerated and safe for both oral and intravenous administration. Sclerotic metaphyseal lines (zebra lines) observed in long bones represent a typical manifestation of cyclic bisphosphonate administration before closure of the epiphyseal growth plate; they do not have negative consequences for bone growth and disappear progressively as they migrate into the diaphysis as a result of bone remodeling [60, 69]. Bisphosphonate treatment may be associated with acute and long-term adverse events (Table 9). The most common acute adverse effect are flu-like syndrome and symptomatic hypocalcemia. Flu-like syndrome usually occurs 1-2 days after the first and/or second course of treatment. However, in our experience, patients with DMD may develop flu-like syndrome after nearly every bisphosphonate administration (unpublished expert data). Symptoms are self-limiting and resolve within hours to a few days by using paracetamol or other analgesic/antipyretic drugs. Nayak et al. [70] reported mild acute-phase reaction after the first zoledronate infusion in most patients with primary or secondary osteoporosis, generally not requiring overnight hospital admission. However, children with DMD, systemic inflammatory disorders, or glucocorticoid-induced osteoporosis often showed more severe acute-phase reactions [37, 38], warranting inpatient monitoring for the first and second intravenous bisphosphonate infusion. In patients with DMD, the acute phase reaction can precipitate signs and symptoms of adrenal insufficiency, necessitating "steroid stress dosing" [37, 38, 55]. Vamorolone may also cause dose-dependent adrenal suppression [71]. Table 9Main adverse effects of bisphosphonates treatment in pediatric patientsAcute adverse effectsAdverse effects associated with long-term useOther potential adverse effectsFlu-like syndrome1Delay in bone healing5Growth impairment8Hypocalcemia2Osteopetrosis-like features by overdosing6Atypical femoral fracture9Hypophosphatemia3Gastrointestinal reflux7Teratogenic effects10Prolonged QTc interval41Mild fever, malaise, nausea, diarrhea, myalgia, arthralgia, bone pain2Asymptomatic or symptomatic3Usually mild and asymptomatic4Secondary to hypocalcemia5Reported after intramedullary rodding procedures, not after a fracture6Metaphyseal widening and sclerosis7By oral administration: severe corrosive esophagitis is a rare complication, not reported in pediatric patients8Unproven9Fractures resembling atypical femoral fractures may occur in children with OI even without bisphosphonate exposure10Significant fetal risks are not reported, but few data are availableFrom Ref. [60], mod Main adverse effects of bisphosphonates treatment in pediatric patients 1Mild fever, malaise, nausea, diarrhea, myalgia, arthralgia, bone pain 2Asymptomatic or symptomatic 3Usually mild and asymptomatic 4Secondary to hypocalcemia 5Reported after intramedullary rodding procedures, not after a fracture 6Metaphyseal widening and sclerosis 7By oral administration: severe corrosive esophagitis is a rare complication, not reported in pediatric patients 8Unproven 9Fractures resembling atypical femoral fractures may occur in children with OI even without bisphosphonate exposure 10Significant fetal risks are not reported, but few data are available From Ref. [60], mod Some studies in adults have shown that the acute-phase response to intravenous bisphosphonates may be related to low vitamin D status [72, 73]. Similarly, in children with OI, low vitamin D concentrations have also been identified as a risk factor for hypocalcemia following intravenous neridronate [74]. In addition to vitamin D deficiency, advanced renal disease and subclinical hypoparathyroidism may contribute to bisphosphonate-induced hypocalcemia [60]. Bisphosphonate-induced hypocalcemia may affect cardiac repolarization, as evidenced by a prolonged QTc interval [75, 76]; however, this adverse effect has not been observed in pediatric patients [60]. To minimize the risk of bisphosphonate-induced hypocalcemia, we suggest administering an intravenous 10% calcium gluconate infusion (0.5 mg/kg body weight per day, diluted in 100 mL isotonic saline solution over a 1-h period) after each bisphosphonate intravenous infusion [77]. Furthermore, all pediatric patients receiving bisphosphonates should maintain serum 25-hydroxyvitamin D (25OHD) concentration ≥ 20 ng/mL, and appropriate dietary calcium intake according to RDAs [38, 60, 78]. Hypocalcemia is rarely reported after oral bisphosphonate administration [60]. Hypophosphatemia following intravenous bisphosphonates is usually mild and asymptomatic; it results from increased parathyroid hormone secretion secondary to the abrupt decline in serum calcium concentration [79]. Growth is not impaired in children receiving bisphosphonate treatment [43]. Significant height gains have been reported in moderately to severely affected patients with OI after four years of cyclical intravenous pamidronate treatment. Preservation or restoration of vertebral height may contribute to improved overall height in patients with moderate OI [80]. However, data from a large cohort of patients with OI demonstrated that individuals with severe forms of OI have reduced height and weight compared to those with type I OI [81]. An atypical radiographic appearance has been observed in about a quarter of nondeformed femoral fractures in children with OI; the atypical femoral fractures appeared to be related to the severity of OI rather than to bisphosphonate treatment history [82]. However, fractures resembling atypical femoral fractures can occur in children with OI who have never received bisphosphonate treatment [43]. Therefore, the role of bisphosphonates in the development of atypical femur fractures in children with OI remains unclear, and it is difficult to distinguish treatment-related effects from those attributable to the underlying genetic disorder [82]. A genetic predisposition to atypical femur fracture has been hypothesized, which could be useful in identifying patients at greatest risk of atypical femur fracture by genetic testing, for whom alternative treatment should be recommended [83, 84]. No recorded cases of medication-related (bisphosphonates) osteonecrosis of the jaw (MRONJ) have been reported in children with OI, despite high cumulative bisphosphonate doses compared with adult practice [43, 85–88]. Nonetheless, some preventive measures before and during bisphosphonates treatment are recommended both in adults [89, 90] and in children [91] (Table 10). Table 10Recommendations and precautions before and during bisphosphonates treatment in children and adolescentsGeneral precautions• Bisphosphonates are still used off-label in pediatric age (except for neridronate for patients with OI in Italy); written consent is mandatory• All patients, irrespective of diagnosis, receiving the first intravenous bisphosphonate dose should be admitted overnight• The first infusion of intravenous bisphosphonate may precipitate adrenal insufficiency in patients on chronic glucocorticoid treatment (e.g. patients with DMD), even when they are taking daily supraphysiological doses1Ensure normal phospho-calcium homeostasis and vitamin D status• Parameters of phospho-calcium metabolism should be assessed and corrected• Subnormal (≤ 20 ng/mL) 25-(OH)D concentrations should be correctedRule out pregnancy• Bisphosphonate are contraindicated during pregnancy• Effective means of birth control to fertile adolescent girls should be prescribed• A pregnancy test should be performed in all fertile adolescent girls before each bisphosphonate doseOral health and oral surgery precautions• All patients should be referred to a dentist for dental and periodontal examination before starting bisphosphonate treatment• Comprehensive dental assessment, and elimination of dental disease or foci of oral infection, before starting bisphosphonate treatment• Attempts should be made to complete all necessary invasive dental procedures before starting bisphosphonate treatment• Patient education for maintenance of optimal dental health• Postpone bisphosphonate therapy until dental health is optimized, or at least until any surgical sites have healed• Perform comprehensive clinical and radiographic examination to identify teeth with a poor or questionable prognosis• In the event of a true dental emergency, invasive dental treatment need not be withheld• In patients receiving bisphosphonates invasive dental procedures would be to carry out towards the end of the infusion cycle, and allowing at least three weeks for soft tissue healing prior to the next infusion• A single pre-operative dose of 2 g amoxicillin for non-allergic patients in a high-risk category undergoing extractions is recommended in children considered to be at the highest risk (no evidence for this recommendation)3Abbreviations: DMD, Duchenne muscular dystrophy1Steroid stress dosing after the first dose of intravenous bisphosphonates is prudent in patients on chronic glucocorticoid treatment, either prophylactically or upon developing symptoms that would normally prompt such intervention [38]2Three weeks would be considered ideal to allow adequate time for healing; consideration should be given to extracting all teeth of questionable prognosis if bisphosphonate treatment has not yet started3According to Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Association recommendations. High-risk factors are invasiveness of surgery, periapical pathology indicating significant bacterial contamination of the surrounding alveolar bone, and receiving bisphosphonate infusions for ≥ 2 years, and having the last infusion within the past two years for children under 14 years, or the past 5 years for children over 14 [91]Nota bene: the effect of bisphosphonate holidays remains controversial Recommendations and precautions before and during bisphosphonates treatment in children and adolescents • Bisphosphonate are contraindicated during pregnancy • Effective means of birth control to fertile adolescent girls should be prescribed • Perform comprehensive clinical and radiographic examination to identify teeth with a poor or questionable prognosis • In the event of a true dental emergency, invasive dental treatment need not be withheld Abbreviations: DMD, Duchenne muscular dystrophy 1Steroid stress dosing after the first dose of intravenous bisphosphonates is prudent in patients on chronic glucocorticoid treatment, either prophylactically or upon developing symptoms that would normally prompt such intervention [38] 2Three weeks would be considered ideal to allow adequate time for healing; consideration should be given to extracting all teeth of questionable prognosis if bisphosphonate treatment has not yet started 3According to Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Association recommendations. High-risk factors are invasiveness of surgery, periapical pathology indicating significant bacterial contamination of the surrounding alveolar bone, and receiving bisphosphonate infusions for ≥ 2 years, and having the last infusion within the past two years for children under 14 years, or the past 5 years for children over 14 [91] Nota bene: the effect of bisphosphonate holidays remains controversial Statement 20. Both oral and intravenous bisphosphonates are generally safe and well tolerated in children and adolescents. Statement 21. Hospital admission for the first and second intravenous bisphosphonate infusion is recommended in patients with DMD, systemic inflammatory disorders, and glucocorticoid-induced osteoporosis. statement 22. Low vitamin D status, advanced renal disease, and subclinical hypoparathyroidism are risk factors for bisphosphonate-induced hypocalcemia. Statement 23. Preventive measures should be implemented in children and adolescents before and during bisphosphonate treatment (Table 10). Other therapeutic options for children and adolescents with bone fragility In addition to bisphosphonates, other pharmacological interventions have been investigated to reduce the risk of fragility fractures, particularly in patients with OI. Some of these approaches are no longer recommended, while others remain under investigation. Historically, calcitonin was widely used in patients with OI, but it was replaced by bisphosphonates due to a poor clinical response and some complications, such as calcitonin dose-related hypomagnesemia [92]. Growth hormone has been administered to improve growth rate in patients with OI [93, 94], but data regarding final height outcomes are lacking. Denosumab therapy has been investigated in patients with OI in comparison with bisphosphonates, and has shown improvements in BMD and spinal morphometry similar to those observed with bisphosphonates [95–97]. However, rebound hypercalcemia has emerged as a frequent and serious adverse effect of denosumab. In one study, 14.3% of patients showed hypercalcemic crisis; intravenous zoledronate can effectively alleviate this side effect [96]. Moreover, compared with alendronate, denosumab was associated with significantly higher risks of hypercalcemia (62.5% vs. 13.3%; P<0.002) [97]. These findings suggest that denosumab is unlike to represent a suitable first-line treatment option for children with OI [98, 99]. Setrusumab, a fully human neutralizing IgG2λ monoclonal antibody targeting sclerostin (injected intravenously monthly), is a promising therapy for patients with OI currently undergoing phase 3 clinical trials [100]. Preliminary data in adults with OI have shown improvements in bone density measured by pQCT [101]. Another anti-sclerostin antibody, romosozumab (injected subcutaneously monthly), is also under evaluation in a phase 3 trial in pediatric patients with OI [102]. Other pharmacological interventions have targeted specific complications in patients with OI type V; indomethacin has been used to reduce hyperplastic callus formation following fracture and osteotomy, although no randomized studies have been conducted [43]. Pain management typically includes paracetamol or ibuprofen, alone or in combination, while opiate use is generally restricted to acute fracture-related pain episodes and perioperative management [43]. Tranexamic acid has been employed to reduce blood loss during operative procedures, thereby shortening post-operative hospitalization [103]. Statement 24. Denosumab is currently not recommended for the treatment of pediatric patients with fragility fractures due to the high risk of adverse effects, particularly rebound hypercalcemia. Conservative measures Conservative measures can play a substantial role in the management of children and adolescents with primary and secondary osteoporosis (Table 11). Optimizing nutrition, maintaining adequate vitamin D status, ensuring sufficient calcium intake, supporting normal pubertal development, and encouraging physical activity, when feasible, may all contribute to maximizing bone mass accrual. However, implementation of these measures may be challenging in patients with chronic diseases, neuromuscular disorders, or cerebral palsy. Table 11Conservative measures in children and adolescents with primary and secondary osteoporosis• Optimize nutritional status• Ensure adequate calcium intake by calcium-rich foods or drinks according to RDAs• Reduce overweight/obesity• Maintain a normal vitamin D status1• Optimize treatment of underlying disease• Use the lowest effective dose of glucocorticoids• Optimize management of osteotoxic medications• Promote physical activity, when feasible• Improve muscle strength, coordination, and muscle contractures, when feasible• Consider pubertal induction in patients with chronic illness and delayed puberty/hypogonadism2• Prevent fractures by avoiding inappropriate handling or movements2• Avoid physical exercises with high-risk activities involving falls and bodily contact• Avoid lifting heavy objects or sports placing excessive stress on the spineAbbreviations: RDAs, recommended dietary allowances1Serum 25-(OH)D concentration between 20 and 50 ng/mL2Particularly in patients with Duchenne muscular dystrophy and cerebral palsy Conservative measures in children and adolescents with primary and secondary osteoporosis Abbreviations: RDAs, recommended dietary allowances 1Serum 25-(OH)D concentration between 20 and 50 ng/mL 2Particularly in patients with Duchenne muscular dystrophy and cerebral palsy Evidence on the efficacy of calcium and vitamin D supplements in improving BMD and reducing fracture rate in children and adolescents with secondary osteoporosis is limited [104–106]. Nevertheless, ensuring adequate dietary intake of calcium and vitamin D is generally recommended in children and adolescents with primary or secondary osteoporosis [33, 38, 39, 98, 107, 108]. Calcium and vitamin D supplements should be individualized according to urinary calcium excretion and serum 25-(OH)D concentration, respectively. Although optimal monitoring intervals are not clearly defined, we recommend assessing serum calcium and 25-(OH)D concentration, as well as urinary calcium excretion, every 4-6 months and within 1-3 months after dose adjustment. In both sexes, delayed puberty [109, 110] and hypogonadism [111, 112] are independent risk factors for reduced BMD and increased fracture risk. Pubertal delay is common in boys with DMD, particularly in those receiving glucocorticoids [55, 113], as well as in patients with cerebral palsy [114, 115]. Therefore, pubertal induction should be considered in patients with recurrent fragility fractures associated with significant pubertal delay [55, 65, 98, 115]. In children and adolescents with malignancies, minimizing exposure to osteotoxic chemotherapic agents and/or glucocorticoids may be useful to reduce the risk of osteoporosis, although this may not be feasible during the acute phase of treatment [33, 38, 65, 98]. Promoting physical activity in children and adolescents with chronic disease or disabilities may be challenging. Rehabilitation programs should be individualized according to disease severity, skeletal involvement, cognitive status, and national healthcare resources. All patients with motor disabilities should participate in structured rehabilitation training programs, including stretching and strengthening exercises [98, 116, 117]. Whole body vibration (WBV) therapy has been reported to improve muscle mass, mobility, and bone health; however, caution is advised in children with severe disabilities, particularly those who are nonverbal and/or have cognitive impairment and/or a Gross Motor Function Classification System level of 4 or 5. WBV should only be performed under the supervision of a qualified physical therapist [98, 118]. General preventive measures to reduce fracture risk should also be implemented, avoiding contact sports, physical exercises with high risk of falls or trauma, and heavy bags or backpacks, and limiting all activities that place excessive strain on spine [108]. Special care must be taken towards children and adolescents with cerebral palsy or neuromuscular disorders to ensure safe transfers from wheelchair to bedroom, bathroom or physiotherapy bed, to minimize fracture risk. Statement 25. Nutrition, vitamin D status, and calcium intake should be optimized in children and adolescents with fragility fractures. Statement 26. a) Physical activity should be promoted according to motor and cognitive abilities. b) Contact sports or activities with a high risk of falls or trauma should be avoided. Statement 27. Delayed puberty and hypogonadism are independent risk factors for reduced bone mass accrual and should be appropriately treated in patients with neuromuscular disorders or cerebral palsy. Conclusions Children and adolescents with bone fragility due to primary or secondary osteoporosis require careful clinical management and individualized treatment. Formal guidelines for the evaluation and treatment of children and adolescents with bone fragility are currently lacking, and most diagnostic and therapeutic decisions rely on the expertise of specialists in pediatric bone disorders. Pediatric bone experts emphasize that osteoporosis diagnosis should be guided primarily by fracture phenotype and clinical context rather than bone densitometry alone. Genetic testing has substantially advanced the identification of disease-causing variants and the discovery of several novel genes linked to bone fragility. A wide range of disorders may predispose to osteoporosis, and they should be systematically ruled out before establishing a diagnosis of primary osteoporosis. Bisphosphonates remain the mainstay treatment in children and adolescents with bone fragility. However, in the absence of international pediatric guidelines, treatment decision should be carefully planned and supervised by clinicians with expertise in pediatric bone disorders. Conservative measures, including optimization of nutrition, calcium intake, and vitamin D status, are recommended, as well as structured rehabilitation training programs, when feasible, in patients with physical disabilities. This expert panel provides a practical guide to the diagnosis, management, and treatment of bone fragility in children and adolescents grounded in current literature and clinical experience. Many of the proposed statements are based on observational data and expert consensus, reflecting the limited availability of randomized pediatric trials. Future high-quality studies are needed to strengthen the evidence base and inform standardized clinical guidelines. Acknowledgments PC is a member of ERN BOND, the European Reference Network for Rare BONe Diseases (https://ernbord.eu/). TA, DC, LdS, ND, AG, SM, MP, and MW are members of Endo-ERN, the European Reference Network for Rare Endocrine Conditions (https://endo-ern.eu/). Funding This manuscript received no external funding. Declarations Conflict of interest All Authors have no conflict of interest to declare. Ethical The paper is based on literature data and clinical expertise and did not require ethics committee approval. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References